There are lots of misconceptions around eczema, from poor hygiene to the skin condition disappearing on its own - there is a ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

An Auckland-based artist living with debilitating symptoms of topical steroid withdrawal (TSW) believes his dermatologists ...

A study found that people who live in places with high levels of air pollution are more likely to have eczema.

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4 ...

Dermatologists have warned that applying adult skincare products and alcohol-based creams on babies puts them at risk of skin ...

Cases of the autoimmune skin condition eczema appear to rise in areas most plagued by air pollution, new research shows.

Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.

EBGLYSS improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with dupilumab. These results from the Phase 3b ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Atopic Dermatitis, commonly known as eczema, manifests as chronic, itchy, and inflamed skin persisting from childhood into adulthood. Contact Dermatitis, triggered by substances, has a prevalence of 4 ...

The California biotech has drawn partnerships with Eli Lilly and J&J on the promise of its approach to rebalancing the immune ...